FDA allows marketing of device to help assess children and teens for ADHD


On June 15, the U.S. Food and Drug Administration (FDA) allowed marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old. The Neuropsychiatric EEG-Based Assessment Aid (NEBA) System is a 15- to 20-minute noninvasive test that calculates the ratio of theta and beta waves. The theta/beta ratio has been shown to be higher in children and adolescents with ADHD. Read more.


Please enter your comment!
Please enter your name here